FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.601,37 -1.215,93 (-2,03%)
DMK Pharmaceuticals Corporation (0A4X.L)
| Chiusura precedente | 0,0360 |
| Aperto | 0,0339 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0339 - 0,0339 |
| Intervallo di 52 settimane | 0,0330 - 8,0500 |
| Volume | |
| Media Volume | 10.485 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,88 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,2730 |
| Prossima data utili | 29 apr 2024 - 04 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAdamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
Company to begin trading under new ticker symbol “DMK” on September 8, 2023SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment of substance use disorders. In conjunction with the name change, the company’s common stock is expected
- GlobeNewswire
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 Corporate Highlights In May, the Company closed the merger with DMK Pharmaceuticals Corporation (DMK), a private, clinical-stage biotechnology company at the forefront of endorphin-inspired drug design focused on de
- GlobeNewswire
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. Each unit was sold at a public offering price of $1.35. The common warrants are immediately exercisable at a price of $1.35 per share and
